

FOR IMMEDIATE RELEASE

UltraGreen.ai Secures Dual Regulatory Approvals in Philippines and Malaysia, Accelerating Expansion Across Southeast Asia

- UltraGreen has obtained regulatory approvals for both its Verdyne in the Philippines and its IC-Flow™ Imaging System V2 in Malaysia
- Dual approvals mark a major milestone following a multi-year regulatory journey and support expansion of fluorescence-guided surgery across Southeast Asia

Singapore, 30th December 2025 — UltraGreen.ai Limited (SGX:ULG) (“**UltraGreen**” or the “**Company**”), a global leader in fluorescence-guided surgery and digital health solutions, today announced regulatory approvals for both its Verdyne (indocyanine green for injection) in the Philippines and its IC-Flow™ Imaging System V2 in Malaysia. The approvals, secured following a long and rigorous regulatory process, marks an important step in the company's strategic expansion across Southeast Asia, a region with rapidly growing healthcare demand.

Fluorescence-guided surgery using ICG has become an increasingly important tool across multiple surgical procedures and specialties. The approval of the IC-Flow Imaging System V2 in Malaysia supports the use of fluorescence imaging technology in clinical settings, while the approval of Verdyne provides clinicians in the Philippines with access to a globally established, high-quality ICG product supported by extensive clinical experience across Europe, US, Asia, and other international markets.

With these approvals in place, UltraGreen and its local partners can now actively support education, training, and broader clinical adoption of indocyanine green (ICG)–based techniques among surgeons in both markets.

Investing in Fluorescence-Guided Surgery Across Southeast Asia

UltraGreen is pursuing a comprehensive, regionally focused approach to building fluorescence-guided surgery. As the Company continues to expand its footprint across Southeast Asia through regulatory approvals, clinical partnerships, and market access initiatives, it provides not only a high-quality imaging dye and compatible products but is also developing an AI-powered data platform designed to further support surgical decision-making and standardisation of care across multiple procedures and specialties.

Commenting on the approval, **Declan Cassells, Chief Operating Officer of UltraGreen**, said:

“These approvals represent far more than regulatory milestones – they pave the way for delivering proven surgical technologies to healthcare systems across Southeast Asia. It is the culmination of a long and demanding journey, and I would like to sincerely thank our dedicated

team for their persistence, regulatory expertise and commitment in bringing Verdyne to the Philippines as well as our IC-Flow Imaging System V2 to Malaysia. Achieving these milestones allows us to deliver on our stated ambition of expanding our presence across Southeast Asia and importantly, to support surgeons in the region with proven fluorescence-guided solutions that can enhance clinical decision-making and patient care. We are committed to supporting these healthcare communities with not just products, but comprehensive training and clinical support, that will elevate the standard of surgical care across the region."

Quek Mei Ling, Chief Business Officer (APAC) of UltraGreen, added: "Southeast Asia is seeing a rapid increase in surgical procedures across oncology, colorectal and reconstructive care. Fluorescence-guided surgery gives surgeons real-time visualisation that can be integrated easily into existing workflows, supporting better intra-operative decisions without adding infrastructure complexity. The IC-Flow system can be used across multiple specialties, making it a highly practical tool as surgical demand continues to grow."

These approvals further strengthen UltraGreen's growing footprint in Southeast Asia and underscore the Company's long-term commitment to advancing precision surgery through high-quality pharmaceutical, imaging and data-driven solutions.



About UltraGreen.ai

UltraGreen.ai Limited (SGX: ULG) is a global leader in the fluorescence-guided surgery space, pioneering vertical AI tools for precision surgery using data-driven fluorescence imaging solutions. UltraGreen offers a fluorescence imaging ecosystem that empowers surgeons with enhanced precision and real-time perfusion data, ultimately improving patient outcomes.

UltraGreen completed its initial public offering on the Singapore Exchange in December 2025, raising US\$400 million at a US\$1.6 billion valuation in the largest non-REIT IPO since 2017. The company is headquartered in Singapore with operations in the United States, Ireland, and offices across Asia-Pacific.

For more information, visit www.ultragreen.ai

Media Contact:

eerong@ultragreen.ai

H/Advisors Klareco: Klareco-Ultragreen@h-advisors.global